PDC-
“At present, many targeted drugs used in clinic are based on monoclonal antibodies. However, the therapeutic application of ADC is limited by its physical, chemical and pharmacodynamic characteristics. PDC has many advantages in using polypeptides as tumor-targeting carriers. Compared with ADCs, they are easy to synthesize and structural modifications can be easily introduced, supporting reasonable drug design to improve bioavailability, affinity and stability. In addition, polypeptides have low immunogenicity.
Two PDC-targeted Sortilin1 (SORT1) receptors currently being developed clinically: TH1902 and TH1904. SORT1 receptors are overexpressed in several malignant tumors, including breast cancer and ovarian cancer. TH1902 is a PDC with a docetaxel payload. It has been fast-track designated by the FDA to treat patients with sortilin-positive recurrent advanced solid tumors that are not effective for standard treatment. TH1902 is currently being studied in the first phase of clinical trials. TH1904 contains an domycin payload and is currently under preclinical research.”
One has to wonder how is that these reports getting published in the China over and over again yet little or none elsewhere?
Anyhow it is good to see the coverage of company’s oncology programs in China.